Andere talen Mabpharm Limited

Aandelen

2181

KYG5780F1046

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:09:09 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,415 ^HKD	-7,78%		-2,35%	-9,78%

26/03	Mabpharm Limited rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
10/01	Livzon Pharma erkent bijzondere waardeverminderingen op kredieten en activa	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Livzon Pharma Recognizes Credit, Asset Impairments	10/01
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	04/12
Mabpharm Limited Announces Director Changes	28/11
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	13/11
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	25-08-23
China Grants Nod to Livzon Pharmaceutical Subsidiary's Clinical Trials for SARS-CoV-2 Booster Shot	17-07-23
Livzon Pharma Raises Cap in Extended Purchase Agreement to 39 Million Yuan	03-07-23
China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy	24-05-23
Mabpharm Grants Jemincare Pharma Unit Promotion Rights to Asthma Drug	13-04-23
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	24-03-23
Chinese Regulator Accepts Mabpharm's New Drug Application for Colorectal Cancer Treatment	15-03-23
Mabpharm Limited Announces New Drug Application of CMAB009	14-03-23
Livzon Pharma's COVID vaccine gets approval as booster in China	02-09-22
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022	26-08-22
China Approves Clinical Trials for Mabpharm's Psoriasis Treatment	28-07-22
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis	27-07-22
Chinese Regulator Approves Mabpharm's Clinical Trial for New Drug	06-07-22
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017	05-07-22
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2021	25-03-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Mabpharm Limited

Aandelen

2181

KYG5780F1046

Andere talen

Filters